ATX.AX

Healthcare Biotechnology

Amplia Therapeutics Limited

A$0.12

+0.01 +4.55% today Live

Price History

Not enough data

Price chart data
Date	Price
Oct 6, 2026, live at 1:11 PM ET	0.12

Key Stats

Market Cap

59.03M

Avg Volume

816,339

EPS

-A$0.02

52W High

A$0.28

52W Low

A$0.10

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-16.43

P/B Ratio

1.49

P/S Ratio

12.32

EV/EBITDA

-3.45

EV/Revenue

6.04

Margins

Gross Margin 92.0%

Operating Margin (185.7%)

Net Margin (160.9%)

EBITDA Margin (174.8%)

Growth & Returns

Revenue Growth (YoY)

(9.1%)

Return on Equity

(25.5%)

Return on Assets

(16.3%)

Liquidity & Leverage

Current Ratio

19.78

Quick Ratio

19.54

Debt / Equity

0.01

Total Cash

27.85M

Total Debt

341,111

About

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.